Trial · NCT05946551
Registered outcomes20
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 20
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants That Had Any Confusion Over How to Take the Study Drug, Including Which Pill to Take, When to Take it, or How Many to Take | End of the Treatment Phase at 12 weeks | The number of participants that had any confusion over how to take the study drug, including which pill to take, when to take it, or how many to take will be recorded as part of the end-of-study survey. |
| Primary | Number of Participants That Had Trouble Adhering to the Study Drug Schedule | End of the Treatment Phase at 12 weeks | The number of participants that had trouble adhering to the study drug schedule will be recorded as part of the end-of-study survey. |
| Primary | Number of Participants That Had Any Difficulty Using the REDCap Interface. | End of the Treatment Phase at 12 weeks | The number of participants that had any difficulty using the REDCap interface will be recorded as part of the end-of-study survey. |
| Primary | Number of Participants That Prefer Participating in This Virtual Study | End of the Treatment Phase at 12 weeks | The number of participants that prefer participating in this virtual study compared to participating in an in-person study hosted at a medical center will be recorded as part of the end-of-study survey. |
| Primary | Number of Participants Satisfied With Their Opportunities to Interact With Study Staff | End of the Treatment Phase at 12 weeks | The number of participants satisfied with their opportunities to interact with study staff will be recorded as part of the end-of-study survey. |
| Primary | Number of Participants That Felt They Could Reach Study Staff if Needed | End of the Treatment Phase at 12 weeks | The number of participants that felt they could reach study staff if needed will be recorded as part of the end-of-study survey. |
| Primary | Number of Participants That Felt That Study Staff Was Available and Easy to Contact to Report Any Adverse Effects | End of the Treatment Phase at 12 weeks | The number of participants that felt that study staff was available and easy to contact to report any adverse effects that they experienced from the medication will be recorded as part of the end-of-study survey. |
| Primary | Number of Participants That Felt That the Amount of Information Collected in Each Series of Surveys Was Acceptable | End of the Treatment Phase at 12 weeks | The number of participants that felt that the amount of information collected in each series of surveys was acceptable will be recorded as part of the end-of-study survey. |
| Primary | Number of Participants That Felt That the Frequency in Which the Information Was Collected Was Acceptable | End of the Treatment Phase at 12 weeks | The number of participants that felt that the frequency in which the information was collected was acceptable will be recorded as part of the end-of-study survey. |
| Primary | Improvement Rating | End of the Treatment Phase at 12 weeks | Participants will be asked how much they feel they improved from this treatment over the last 12 week using a scale from 1 to 5, with 5 being complete improvement (better outcome) and 1 being no improvement. |
| Primary | Quality of Life (QoL) Score Rating | End of the Treatment Phase at 12 weeks | Participants will be asked how much their quality of life was impacted by changes to their health during the study. On a scale of 1 to 5 with 5 being the most impacted (better outcome) and 1 being not at all impacted by changes to their health. |
| Primary | Interest Score | End of the Treatment Phase at 12 weeks | Participants will be asked how interested they are in continuing treatment with the study medication after the study. On a scale of 1 to 5, with 5 being completely interested (better outcome) and 1 being completely uninterested. |
| Secondary | Proportion of Survey Completion | End of the Treatment Phase at 12 weeks | Percentage of participants who complete 70% of surveys will be assessed |
| Secondary | Proportion of Study Drug Adherence | End of the Treatment Phase at 12 weeks | Percentage of participants who complete 70% of doses will be assessed |
| Secondary | Proportion of Lost to Follow Up (LFUP) | End of the Treatment Phase at 12 weeks | Percentage of participants Lost to Follow Up (LFUP) will be assessed |
| Secondary | Proportion of Voluntary Termination | End of the Treatment Phase at 12 weeks | Percentage of participants that voluntarily terminate participation will be assessed |
| Secondary | Adverse Events (AEs) Incidence | End of the Treatment Phase at 12 weeks | The mean number of adverse events in the treatment arms will be compared to those in the placebo arm. |
| Secondary | Serious, Unexpected Suspected Adverse Reactions (SUSAR) Incidence | End of the Treatment Phase at 12 weeks | The number of SUSARs in the treatment arms versus the placebo arm will be recorded. |
| Secondary | Study-wide Serious Adverse Events (SAEs) Incidence | End of the Treatment Phase at 12 weeks | The total number of SAEs in the treatment arms versus the placebo arm will be recorded. |
| Secondary | Number of Discontinuations or Temporary Suspensions of IP | End of the Treatment Phase at 12 weeks | The total number of participants who discontinue any of the treatment arms versus the placebo arm will be recorded. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05946551/registered